Sandoz Deal History & Licensing Activity
Sandoz is a large pharma headquartered in Switzerland. Over the past three years, Sandoz has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals). The company currently has 3 active clinical trials, primarily in Other.
Deals (12mo)
2
Active Trials
3
Top Modality
Antibodies
Focus Area
Other
Sandoz Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sandoz in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HLX05-N, HLX16, belimumab biosimilar, HLXTE-HAase1001 | Shanghai Henlius Biotech, Inc. | Antibodies | Preclinical | collaboration | Aug 17, 2026 |
| Biosimilar products (3 initial biosimilars plus option on 4th asset) | Henlius | Other | Unknown | option | Aug 17, 2026 |
Sandoz Pipeline Focus
Therapeutic areas and modalities where Sandoz is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Sandoz Strategic Signals
Key indicators of Sandoz's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Sandoz Clinical Pipeline
Sandoz has 3 active clinical trials across 2 development phases.
2
Unknown
1
Phase 3
See How Your Asset Matches Sandoz's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Sandoz Licensing & Deal Activity
Sandoz is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Sandoz ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sandoz include Other (4 deals and trials), Autoimmune (2 deals and trials), and CNS Disorders (1 deal and trial). In terms of modality, Sandoz has shown particular interest in antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sandoz and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Sandoz's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.